Qingxia Fan

468 total citations
17 papers, 156 citations indexed

About

Qingxia Fan is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Qingxia Fan has authored 17 papers receiving a total of 156 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 11 papers in Pulmonary and Respiratory Medicine and 7 papers in Surgery. Recurrent topics in Qingxia Fan's work include Cancer Immunotherapy and Biomarkers (8 papers), Esophageal Cancer Research and Treatment (7 papers) and Gastric Cancer Management and Outcomes (6 papers). Qingxia Fan is often cited by papers focused on Cancer Immunotherapy and Biomarkers (8 papers), Esophageal Cancer Research and Treatment (7 papers) and Gastric Cancer Management and Outcomes (6 papers). Qingxia Fan collaborates with scholars based in China and Ethiopia. Qingxia Fan's co-authors include Tianshu Liu, Weiguo Su, Wensheng Qiu, Ye Guo, Mei Feng, Yanqiao Zhang, Yue Ma, Ruifang An, Nong Xu and Guiling Li and has published in prestigious journals such as Journal of Clinical Oncology, British Journal of Cancer and European Journal of Cancer.

In The Last Decade

Qingxia Fan

17 papers receiving 153 citations

Peers

Countries citing papers authored by Qingxia Fan

Since Specialization

Citations

This map shows the geographic impact of Qingxia Fan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Qingxia Fan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Qingxia Fan more than expected).

Fields of papers citing papers by Qingxia Fan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Qingxia Fan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Qingxia Fan. The network helps show where Qingxia Fan may publish in the future.

Co-authorship network of co-authors of Qingxia Fan

This figure shows the co-authorship network connecting the top 25 collaborators of Qingxia Fan. A scholar is included among the top collaborators of Qingxia Fan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Qingxia Fan. Qingxia Fan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

#	Work	Indexed citations
1	Anti-PD-L1 envafolimab combined with anti-VEGF suvemcitug in pretreated solid tumors and hepatocellular carcinoma: an open-label phase II study with safety run-in stage 2025 ·Investigational New Drugs ·(unknown), Yu Zhang, Yong Fang, Chunyi Hao, Qingxia Fan, (unknown), Liqin Lu, (unknown), (unknown), (unknown), Tianhao Ji, (unknown), (unknown), Ying Cheng	2
2	Update results of anlotinib combined with TQB2450 (PD-L1 blockade) as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): A single-arm, multicenter, open-label phase II clinical trial. 2024 ·Journal of Clinical Oncology ·Xiangrui Meng, (unknown), (unknown), Zhiye Zhang, (unknown), Yunfang Chen, Tao Wu, Zhengzheng Shan, Qingxia Fan, Feng Wang	2
3	Safety and efficacy of Pucotenlimab (HX008) - a humanized immunoglobulin G4 monoclonal antibody in patients with locally advanced or metastatic melanoma: a single-arm, multicenter, phase II study 2023 ·BMC Cancer ·Chuanliang Cui, Yu Chen, Zhiguo Luo, Zhengyun Zou, Yu Jiang, Hongming Pan, Qingxia Fan, (unknown), Qing Xu, (unknown), Xuan Wang, (unknown), Zhen Guo, Lu Si, Zhihong Chi, Xinan Sheng, (unknown), Qian Tan, Di Wu, Jun Guo	6
4	Anlotinib combined with TQB2450 (PD-L1 blockade) as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): A single-arm, multicenter, open-label phase II clinical trial. 2023 ·Journal of Clinical Oncology ·(unknown), Xiangrui Meng, (unknown), Zhiye Zhang, (unknown), Tao Wu, Yunfang Chen, Zhengzheng Shan, Qingxia Fan, Feng Wang	2
5	Updated results of anlotinib combined with TQB2450 (PD-L1 blockade) as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): A single-arm, multicenter, open-label phase Ⅱ clinical trial. 2023 ·Journal of Clinical Oncology ·Zhiye Zhang, Xiangrui Meng, (unknown), (unknown), (unknown), Yunfang Chen, Tao Wu, Zhengzheng Shan, Qingxia Fan, Feng Wang	2
6	Camrelizumab plus apatinib for immunochemotherapy-treated advanced esophageal squamous cell carcinoma: Preliminary results of cohort 2 in CAP 02 study. 2023 ·Journal of Clinical Oncology ·Feng Wang, Junsheng Wang, Xiangrui Meng, (unknown), (unknown), (unknown), (unknown), Yinghua Ji, Zhengzheng Shan, Qingxia Fan	3
7	A phase Ib/II, multicenter, open-label study of AK104, a PD-1/CTLA-4 bispecific antibody, combined with chemotherapy (chemo) as first-line therapy for advanced gastric (G) or gastroesophageal junction (GEJ) cancer: 2-Year update data. 2023 ·Journal of Clinical Oncology ·Jiafu Ji, Lin Shen, Ziyu Li, Xiangyu Gao, Ke Ji, Ye Chen, Nong Xu, Tianshu Liu, Nong Yang, Haijun Zhong, Changzheng Li, Zengqing Guo, Qingxia Fan, Xiaoyan Lin, (unknown), Wei Liu, Zhongmin Maxwell Wang, Baiyong Li, (unknown)	5
8	Osemitamab in combination with capecitabine and oxaliplatin (CAPOX) as a first line treatment of advanced G/GEJ cancer: Updated data of cohort C from a phase I/IIa, multi-center study (TranStar102/TST001-1002). 2023 ·Journal of Clinical Oncology ·Lin Shen, Dan Liu, (unknown), Weijian Guo, Tianshu Liu, Hongli Li, Jiayi Li, Yuxian Bai, Yanhong Deng, Zhixiang Zhuang, Meili Sun, Qingxia Fan, (unknown), Liang Han, (unknown), Jianming Wang, (unknown), (unknown), Xueming Qian, Caroline Germa	13
9	Composite films based on Bi2Se3 nanosheets and carbon nanotubes with photothermal and photodynamic functions for synergistic treatment 2023 ·Materials & Design ·Yu Meng, Congcong Wang, Lijie Song, (unknown), (unknown), (unknown), Gongxun Bai, Qingxia Fan	6
10	Serplulimab, a novel anti-PD-1 antibody, in patients with microsatellite instability-high solid tumours: an open-label, single-arm, multicentre, phase II trial 2022 ·British Journal of Cancer ·Shukui Qin, Jin Li, Haijun Zhong, Chuan Jin, Lili Chen, Xianglin Yuan, Qingxia Fan, (unknown), Peiguo Cao, (unknown), Da Jiang, Tao Zhang, Hongyu Zhang, Xicheng Wang, Wei Wang, Han Lin, Qingyu Wang, Junwu Zhu, (unknown)	15
11	Paclitaxel and cisplatin with or without cetuximab in metastatic esophageal squamous cell carcinoma: a randomized, multicenter phase II trial 2022 ·The Innovation ·Zhihao Lü, Yanqiao Zhang, Qingxia Fan, Yueyin Pan, Da Jiang, Ping Lu, Jingdong Zhang, Xianglin Yuan, Jifeng Feng, Shujun Yang, Wenbin Yue, Lin Zhao, Yunhua Xu, Jinhua Luo, Lin Shen	9
12	Updated efficacy and safety results from the phase 2 study of serplulimab, a novel anti-PD-1 antibody, in patients with previously treated unresectable or metastatic microsatellite instability-high or mismatch repair-deficient solid tumors. 2022 ·Journal of Clinical Oncology ·Jin Li, Shukui Qin, Haijun Zhong, Chuan Jin, Lili Chen, Xianglin Yuan, Qingxia Fan, (unknown), Peiguo Cao, Jianjun Xiao, Da Jiang, Tao Zhang, Hongyu Zhang, Xicheng Wang, Wei Wang, Han Lin, Qingyu Wang, Jun Zhu, (unknown)	1
13	Phase 1b/2 trial of fruquintinib plus sintilimab in treating advanced solid tumours: The dose-escalation and metastatic colorectal cancer cohort in the dose-expansion phases 2022 ·European Journal of Cancer ·Ye Guo, Weijie Zhang, Jieer Ying, Yanqiao Zhang, (unknown), Wensheng Qiu, Qingxia Fan, Qi Xu, Yue Ma, Gang Wang, (unknown), Weiguo Su, Songhua Fan, (unknown), Yan Wang, Yang Luo, Hui Zhou, Jin Li	31
14	Apatinib inhibits tumour progression and promotes antitumour efficacy of cytotoxic drugs in oesophageal squamous cell carcinoma 2022 ·Journal of Cellular and Molecular Medicine ·Yan‐Yan Chi, Feng Wang, Yana Zhang, Zhengzheng Shan, (unknown), (unknown), Dao Xin, Qingxia Fan, Yan Sun	11
15	355. CAMRELIZUMAB COMBINED WITH CHEMOTHERAPY OR APATINIB AS NEOADJUVANT THERAPY FOR LOCALLY ADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA: A PHASE 2 TRIAL 2022 ·Diseases of the Esophagus ·(unknown), Xiangrui Meng, Zhengzheng Shan, Qingxia Fan, Feng Wang	1
16	Efficacy and safety of cadonilimab, an anti-PD-1/CTLA4 bi-specific antibody, in previously treated recurrent or metastatic (R/M) cervical cancer: a multicenter, open-label, single-arm, phase II trial (075) 2022 ·Gynecologic Oncology ·Xiaohua Wu, Jiafu Ji, Hanmei Lou, Yunxia Li, Mei Feng, Nong Xu, Yuzhi Li, Jing Wang, Yi Huang, Ge Lou, Ruifang An, Changzheng Li, Qi Zhou, (unknown), Enfeng Zhao, Tianshu Liu, Qingxia Fan, Guiling Li, Baiyong Li, Yu Xia	44
17	Camrelizumab in combination with preoperative chemotherapy for locally advanced esophageal squamous cell carcinoma: A single-arm, open-label, phase II study. 2021 ·Journal of Clinical Oncology ·Feng Wang, (unknown), Xiangrui Meng, Qingxia Fan	3

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact